The Phase II study for diabetes is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate ...

Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced ...

Opening with Florida and Kentucky looked incredibly daunting at the start of the year. Florida was preseason #2, and Kentucky ...

A study from MoneySuperMarket used 27,000 reviews to determine the airlines with the best food. The top 20 carriers hailed ...

Alkermes (ALKS) shifts to fully integrated biopharma, leveraging Vibrance-2, Lybalvi growth, and Avadel buy to de-risk ...

It sounds like Lilly did just that. The U.S. pharma announced Wednesday that it was paying $14 per share of Ventyx—more than ...

Atea continues to advance its global Phase 3 program evaluating the fixed-dose combination (FDC) of BEM, a nucleotide analog ...

Takeda and Protagonist Therapeutics have submitted a new drug application to the FDA for rusfertide for adults with ...

The Sycamore Youth Center has announced registration is open for after-school classes for the winter and spring semester. Classes run from Jan. 26 through May 1, with courses offered to students in ...

Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations KB407 transduction confirmed in all six patients with successful bronchoscopies irrespect ...

Encouraging anti-tumour activity seen across all dose levels and in various tumour indications Clinical benefit rate of 80% ...

Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer ...